Business Wire

REPLY: The Jury for the Second Edition of the Reply AI Film Festival Is Announced, Which Will Celebrate the Best AI-generated Short Films

8.5.2025 11:23:00 CEST | Business Wire | Press release

Share

Gabriele Muccino, together with Caleb & Shelby Ward, Caroline Ingeborn, Charlie Fink, Denise Negri, Dave Clark, Filippo Rizzante, Guillem Martinez Roura, Paolo Moroni, and Rob Minkoff, will evaluate the shortlisted films based on creativity, production quality, and the use of Artificial Intelligence.

Reply, an international group specialised in the development of new business models enabled by Artificial Intelligence and long committed to the exploration of emerging technologies and supporting the growth of new talent, announces the jury for the second edition of the Reply AI Film Festival. The international competition open to creatives, filmmakers, and videomakers who wish to experiment with the production of short films using AI tools and explore the continuous evolution of the collaboration of human creativity and technology and the power that this combination brings to storytelling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508567831/en/

The jury for the second edition of the Reply AI Film Festival is announced, which will be held during the 82nd Venice International Film Festival (Photo: REPLY)

The jury will be chaired by Gabriele Muccino, an Italian director and screenwriter known for films such as The Pursuit of Happyness, and Seven Pounds. Joining him on the panel for the second edition of the Reply AI Film Festival are returning members Rob Minkoff, co-director of The Lion King and creator of numerous films including Stuart Little, The Haunted Mansion, and Mr. Peabody & Sherman; Caleb & Shelby Ward, co-founders of Curious Refuge, the first online community dedicated to filmmakers using Artificial Intelligence; and Denise Negri, journalist for SkyTg24 and Sky Arte, and correspondent for major international film events such as the Academy Awards, Cannes, and Venice Film Festivals. New to the jury this year are Dave Clark, founder and Chief Creative Officer of Promise, a production company focused on films, series, and innovative formats created in collaboration with some of the world’s most talented GenAI artists and storytellers worldwide, and Charlie Fink, columnist for Forbes US and expert in Augmented Reality, Virtual Reality, and AI. The jury also includes Filippo Rizzante, Chief Technology Officer at Reply; Caroline Ingeborn, Chief Operating Officer at Luma AI, a platform for creating highly realistic 3D images and videos; Paolo Moroni, Head of Lexus Italy; and Guillem Martinez Roura, AI & Robotics Lead at ITU AI for Good, the United Nations initiative focused on harnessing AI for the benefit of society.

The theme chosen for the 2025 edition is "Generation of Emotions" — an invitation to explore how Artificial Intelligence can evoke authentic and engaging emotions through cinematic language. The jury will evaluate submissions — due by June 1st, 2025 via the platform aiff.reply.com — based on creativity, production quality, and the use of AI in the various stages of development, from script to post-production.

Gabriele Muccino commented:The Reply AI Film Festival is a pioneering event showcasing technology and art's exciting intersection. AI is not a replacement for human creativity, but a catalyst for innovation. It will enable filmmakers to explore new styles, genres, and narratives that were previously unimaginable. As President of the Reply AIFF Jury, I'm honoured to be part of this journey, discovering new talents and celebrating the bold experiments that will shape the future of cinema. The AI revolution is just beginning, and I'm thrilled to be at the forefront of this creative explosion.”

“The role of AI in the future of the film industry won’t be about replacing filmmakers—it’ll be about expanding what’s creatively possible. It will be a creative collaborator, helping filmmakers visualise ideas faster, experiment more freely, and bring ambitious stories to life with fewer limitations. From pre-production to post, AI will streamline workflows and democratise access to powerful tools, opening doors for more diverse voices and bold storytelling. But filmmaking will always be human at the core because AI can’t feel joy, loss, or love. It hasn’t lived the stories we’re here to tell. Used with intention, AI won’t diminish creativity but elevate it,” said Dave Clark founder and Chief Creative Officer of Promise.

We are delighted to launch the second edition of the AI Film Festival because we believe in the importance of creating spaces and opportunities to experiment with emerging technologies,” said Filippo Rizzante, CTO of Reply. “The success of the first edition, with over 1,000 short films submitted from 59 countries, underlinesthe globalinterest — not only among the younger generations — in initiatives that challenge both technical and creative skills.”

In addition to selecting the most outstanding original short films, the jury will also award two special prizes that are new to this edition: the Lexus Visionary Award, recognising the most visionary and innovative production that successfully integrates technology, design and forward-thinking, in line with the values that have always guided Lexus' approach to creativity; and the AI for Good Award, promoted in partnership with the International Telecommunication Union (ITU), which recognises the best short film that highlights the United Nations Sustainable Development Goals (SDGs).

Paolo Moroni, Head of Lexus Italy, commented: “It is an honour to be part of the jury for this festival, which invites us to explore how Artificial Intelligence can accelerate the creation of authentic and engaging emotions through the language of cinema, combining innovation, creativity and vision. Much like Lexus - with whom it shares values such as innovation, creativity and forward thinking - this competition celebrates the evolution of film and technology's ability to support the generation of deep emotions, constantly pushing the boundaries of imagination.

“I'm thrilled to join the Reply AI Film Festival as a juror and to present the 'AI for Good Award'. This festival is a unique opportunity to showcase the creative potential of generative AI technologies in storytelling. I'm looking forward to seeing how filmmakers use AI to tell compelling stories, highlighting the importance of sustainable development. AI can be a powerful tool for driving positive change, and I'm excited to see how the festival will inspire new ideas and innovations," said Guillem Martinez Roura, AI & Robotics Lead at ITU "AI for Good"

The creatives behind the shortlisted works will be invited to a premiere event, organised by Reply and Mastercard, taking place in September in Venice where the three overall winners will be officially announced.

Reply

Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508567831/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye